Hillgene, based in China, has built an integrated cell therapy development pathway covering discovery through clinical delivery. The company operates dedicated nucleic acid production platforms, serum-free suspension cell culture systems, and fully closed process development and quality control workflows for cell therapy manufacturing. These platforms support the development of CAR-T, TCR-T, and stem cell–based products in collaboration with multiple partners.
